Razadyne ER is a prescription drug known as acetylcholinesterase inhibitor (or AChEI) and is marketed as a treatment for mild to moderate symptoms associated to Alzheimer’s disease (memory loss for instance). While the exact way the drug works is not known, experts believe that it blocks an enzyme that breaks down Acetylcholine (ACh) in the brain, thus ensuring the presence of more ACh. Specialists found that patients with Alzheimer’s have low levels of ACh, chemical which helps with learning, memory and functioning skills.
Razadyne is manufactured by Janssen Pharmaceuticals (former Ortho-McNeil Neurologics), but is also available as a generic drug, since it has come off patent. The manufacturer is a US based pharmaceutical company, part of the Johnson & Johnson multinational.
Razadyne ER Ingredients
Razadyne ER includes the following ingredient: Galantamine Hydrobromide.
The manufacturer claims clinical trials have been conducted to test the drug’s efficiency. The dosage of Razadyne ER shown to be effective in a controlled clinical trial is 16-24 mg/day.
Side effects commonly associated with the product are nausea, diarrhea, vomiting, weight loss and loss of appetite. An extended list of possible side effects includes: chest pain, confusion, extreme thirst, decreased sweating or slow heart rate.
Razadyne is available in short-acting forms (tablets and oral solution) which should be taken twice a day and in long-acting once-daily dose Razadyne ER (Extended Release) capsules.
Before starting treatment, a thorough doctor’s evaluation is recommended. Precautions include, but are not limited to patients with hepatic or renal impairment.
The manufacturer claims the medication should be used regularly in order to get the most benefit from it. Dosage increase or decrease, as well as interrupting treatment should only be done under doctor’s instructions.
- Good manufacturer reputation
- Clinical trials to prove efficiency
- FDA approved
- Clear use directions
- Potential severe side effects
Razadyne ER consumer reviews are generally positive mentioning improvement in the performance of day-to-day activities. However, decreasing efficiency as the disease progresses has been reported by patients. Various side-effects ranging from mild to severe have been associated with the product.
The manufacturer mentions clinical trials which prove the drug’s efficiency in treating symptoms associated to early stages of Alzheimer’s Disease. The drug is FDA approved and is released based on a doctor’s prescription.
Although the way it works is not fully understood, specialists believe the drug works to keep up levels of a certain chemical in the brain called Acetylcholine, substance responsible for the good functioning of the memory and learning abilities.